The ProteinOne improved c-Myc oncoprotein (cat.# P2015) has now been joined in the catalog by its homo and heterodimer binding partner MAX (Myc -Associated Factor X, cat.# P2031) and MAD (MAX dimerization protein 1, cat# P2030). In launch recognition of this key combo, when you purchase both c-Myc and MAX together you will save 10%, limited time only. Myc, MAD and MAX proteins affect different aspects of cell behavior, including proliferation, differentiation, and apoptosis, by modulating distinct target genes. These new products will enhance understanding of their mediation in key biological systems.

In an effort to advance systems biology research, ProteinOne offers protein mutation or modification services which may very well enhance understanding of these protein alterations in mediating biological activities. The company provides custom sequence, phosphorylation (signaling pathways), or biotinylation (affinity chromatography, protein detection imaging) additions / changes which help monitor outcome related to these modifications advancing individual scientific projects. High quality, affordable custom protein or bulk scale up proposals can be provided upon request. Click here to request proposal.

ProteinOne will participate in the exciting developments surrounding the Endocrine Society's 2006 Annual meeting in Boston. Considered the largest gathering of endocrinologists, ProteinOne will enhance scientific development in endocrinology by promoting its leading catalog of Nuclear Hormone receptors and high demand ProPure Custom Protein Service. Stop by booth 1112 in the "Research Park" section of the ENDO exhibit area to find out how P1 can advance your research. We look forward to meeting you.

ProteinOne invites Pharmaceutical Scientist to visit their booth at the upcoming PharmaDiscovery Conference, Bethesda MD, May 10-12, 2006. This year's conference takes place at the Bethesda North Marriott Hotel and Conference Center and will be focused on the innovation in drug discovery and development and will bring together top scientists from pharmaceutical, biotechnology and academia.

BioScience Technology magazine's upcoming May issue "Finding the Needle, Protein Analysis Methods" will feature contributions from ProteinOne scientist. The article reviews the proteomic advancements and present challenges of which ProteinOne actively provides solution leadership. Jeannette Webster, PhD, Senior Scientist provides commentary and Lawrence Charity, Director of Marketing & Business Development is featured on the cover.

ProteinOne again raises the standard of technology with the introduction of its NEW ProSHIFT(tm)-Gel Shift Assays. These inventive new EMSA (Electrophoretic Mobility Shift Assay) take the Gel Shift concept to a level of greater accuracy and specificity using purified whole proteins vs the previous cell extract interaction assays. The known identity of the recombinant protein in the assay eliminates further need for Super shift assay confirmatory testing. Another exciting ProSHIFT(tm) Gel Shift Assay feature is the novel use of Binding Partners for proteins which bind DNA as a heterodimer.

The currently available ProSHIFT(tm)- Gel Shift Assay Kits are:

- GR (Glucocorticoid Receptor) Cat.# P6000-01,
- PPAR alpha (Cat.# P6001-01)
- PPAR beta (Cat.# P6002-01)
- PPAR gamma (Cat.# P6003-01)
- PPAR Triad (Cat.# P6004-01) All 3 PPAR isoforms in one kit.

The 2006 will bring exciting new innovative additions to the ProteinOne bioreagent catalog. The highly anticipated Active Protein Array, Nuclear Receptor Array will be launched mid-January in two unique formats, Nitrocellulose Membrane and Glass Slide. This Array product platform will represent the most unique, largest collection of full length, active Nuclear Receptors in one high throughput assay. It is the premiere array to contain "heterodimer receptor targets" for more accurate results and greater binding efficiency. Other new developments include expansion of the Transcription array format to add a Nitrocellulose glass slide version, the addition of 10 New Protein Kinases and expanded distribution channels for increased customer accessibility.

A Protein Kinase category has been added to the 2006 ProteinOne Product Catalog to mark to launch of 10 new Kinase products. The activity validated new protein Kinases include: Breast cancer related- PIP5K2 beta (Cat.# P5007), potential cancer therapeutic - PLK1 (Cat. #P5008), immunity related - LCK (Cat. #R5024), antioncogene - CSK (Cat.# R1090), angiogenesis - MAPK14 (Cat.# R5048), I-GLK (Cat.# P5051), L-GLK (Cat.# P5052), SNARK NUAK2 (Cat. # P5053), SNARK MT (Cat.# P5054), and PTPN1 (Cat. #P5110). For the month of January, save 10% when you purchase any new Kinase.

ProteinOne will introduce the New Nuclear Receptor Array of it's Active Protein Array platform and promote it's Expression & Purification Service at the up coming NIH Research Festival Exhibit, Oct 20-21, 2005. The NR Array will be launched early next year and the details with be available at the ProteinOne booth # 854 of the annual event. The NIH has had a long standing and growing relationship with company, this exhibit annually enhances that partnership.

ProteinOne entered into the infectious disease market with the release of its new HIV Protease (Cat. #P5102) and new Hepatitis C -NS3/4A Protease (Cat.# P5101). Protease is a chemical, known as an enzyme, that HIV and HCV need in order to make new viruses. HIV Protease inhibitors offer new hope of a combined approach to HIV infection and ProteinOne's unique protein will contribute to the development of new inhibitors with fewer side effects. The company is in a leadership position by having these very high purity Proteases, the quality and availability of which are unequaled in the current protein reagent market.

ProteinOne's value added product quality and protein activity are confirmed. Ligand binding activity of nuclear hormone receptors can be indirectly measured through the ligand-dependent interaction between the receptor and cofactors such as steroid receptor coactivator 1 (SRC1). The quality improvement data shows that the PPAR gamma ligand indomethacin increases the interaction between purified SRC 1 receptor interaction domain (SRC1 RID) (Cat. No. P1080) and purified GST-PPAR gamma LBD (Cat. no. P4036). This validation documents the protein ligand binding and confirms activity of ProteinOne's protein. For more detailed information, contact us a info@proteinone.com.

ProteinOne is establishing itself as the premiere leader in the human protein expression and purification business. Not all protein purification and expression facilities are created equal. Many companies and institutions offer protein services but, upon completion of these protein isolations, the yield is very little if any protein at all for their efforts at a high cost. ProteinOne's completion rate is nearly 100% and approaching 300 proteins successfully purified. The high quality, purity and full length proteins produced by the company enable requesting medical researchers to proceed uninterrupted with confidence in their intended experiments. ProteinOne provides a complete service including cloning, expression and purification, from beginning to the end where other companies may not. (Press Release)

Cell-BasedBio^TM of Austin, TX entered an agreement with ProteinOne which will extend that company's products and capabilities to include high purity, active proteins and protein purification services. Cell-BasedBio^TM delivers products and services to private, academic and government research institutions, and pharmaceutical and biotech companies worldwide. Cell-BasedBio^TM 's own research and development efforts are intended to be pioneering initiatives focused on new technologies in all major areas of biology, biochemistry and biomolecular screening. This alliance with ProteinOne augments their functional genomic initiative enabling them to now provide value added proteomic solutions for their customers.

ProteinOne recently released a new improved version of the pivotal c-Myc oncoprotein. The new c-Myc (Cat.# P2015) improves on an already high standard with increased purity, greater stability which creates less degradation and higher activity for improved reactivity in vitro experimentation. The c-Myc promoter integrates diverse mitogenic signaling cascades, which are constitutively activated in tumor cells, and translates them into expression of the c-Myc transcription factor, which promotes cell proliferation, growth, differentiation, and apoptosis by regulating the expression of numerous target genes. This new c-Myc protein will greatly impact the quality and accuracy of cancer research results.

ProteinOne extends its global presence to India and South Asia with the signing of a distribution partnership with Life Technologies (India) Pvt. Ltd. With the initiatives taken by the government, Indian Biotechnology is poised for tremendous growth. The biotechnology sector in India is growing rapidly at a rate of over 40 percent annually. India is the largest producer of recombinant Hepatitis B vaccine in the world today. The country is also emerging as global player in recombinant Human Insulin. ProteinOne and Life Technologies (India) will enable new science applications in making accessible to the Indian research community its leading catalog of recombinant proteins and custom protein purification services.

ProteinOne recently released the first in its series of highly anticipated Signal Transducer and Activator of Transcription (STAT) proteins. The STAT3 - Signal Transducer and Activator of Transcription 3, (Cat.# 1071) is a family member of latent cytoplasmic transcription factors involved in cytokine, hormone and growth factor signal transduction. STAT3 is showing evidence as a key player in the pathogenesis of diverse human cancers including prostate, ovarian, head and neck which makes this molecule a prime target for novel therapies. Also, its newly discovered role in the initiation and promotion stages of skin cancer and Chron's disease, intensive efforts are now focused on researching the proteins activated by STAT3

This nuclear receptor, called peroxisome proliferator-activated receptor (PPAR) delta, may be involved in chronic diseases such as diabetes, obesity, artherosclerosis and cancer. ProteinOne now offers the new GST tagged PPAR-delta-LBD which adds to the list of existing PPAR products. Like PPARβ, PPAR delta is found in many tissues but the highest expression is in the gut, kidney and heart. It has also been reported as an activator of COX-2 gene expression in carcinoma cells.

ProteinOne continues leading the advancement in protein science by announcing today its relocation to their new administrative offices and laboratories on March 21, 2005. The new 9000 sq.ft. facility (located 6931 Arlington Road, Suite T100, Bethesda, MD 20814) centers the company near the National Institute of Health, National Naval Medical Center and in the growing Montgomery County Biotechnology corridor which makes way for continued growth and business expansion. The move validates ProteinOne's ongoing success with its functional genomic protein bioreagents, Active Protein Array Platforms and reputable ProPure custom protein services.

ProteinOne continues to make contributions to the systems biology discovery arena with products cited in recent scientific publications. P1 is cited as a protein interaction biochip company in the recent issue of Nature Biotechnology. In the issue, it comments that " The early analogies between proteomics and genomic analysis have been either overly simplistic or completely misleading, as the level of complexity in the former is orders of magnitudes higher." Dolores Cahill, director of the Center for Human Proteomics at the Dublin-based Royal College of Surgeons is quoted as saying "I think there is now a bit more realism about the expertise and the infrastructure required to do good proteomics studies".
ProteinOne provides protein solutions and enables genomic researchers to realistically face this new frontier. Other recent ProteinOne citations include:

Addressing the need to further understand acute inflammatory response, ProteinOne has just released a new HMG1 protein with low Endotoxin levels. This new version of HMG1, (High Mobility Group 1 protein, Cat# P1025) has extremely low levels of endotoxin at <0.25 EU/ml by LAL testing and further enhances the already established high purity >95% of this protein which is a late mediator of delayed endotoxin lethality that activates downstream cytokine release. This new product along with ProteinOne's highly specific HMG1 Antibody (Cat# PA112-01) will contribute to advancing HMG1 as a therapeutic marker. P1 works hard to provide the very best proteins available, and our customers have come to count on this level of quality and service.

ProteinOne is starting the new year with a special introductory offer on its new Active Protein Array, Transcription Array Kit. For the month of January, when you purchase the 36 Activated Transcription Array (Cat# 8001) you will get 2 (two) kits for the price of one. For price and order information log in to the ProteinOne Online E-Order center. The new protein microarray or "biochip" platform will allow the high throughput characterization of multiple proteins simultaneously and is expected to have a major impact on the proteomics array market. (Link to press release) Offer expires May 31, 2005.

Now available are the frequently requested LBD for the three isotypes of PPAR, alpha (Cat.# P1063), beta (Cat.# P1064) and gamma (Cat.# P1065). These protein products of related nuclear receptors will continue the ProteinOne standard of quality for researchers working on deciphering such chronic diseases as diabetes, obesity, arteriosclerosis and cancer.

The new GST tagged, Human Upstream Stimulatory Factor 1 (Cat# P4032)regulates transcription of many genes associated with lipid, glucose homeostasis and complements the existing USF1 product (Cat# P1062) in offering researchers additional bioreagents for in vitro transcription, DNA binding and protein-protein interaction assays.

ProteinOne continues leading the advancement in protein science by announcing today the greatly anticipated release of its new Active Protein Arraya. The new protein microarray or "biochip" platform will allow the high throughput characterization of multiple proteins simultaneously and is expected to have a major impact on the proteomics array market. (Link to press release)

ProteinOne recently presented its functional discovery company at the Bio.Life.Tech 2004 Conference in Baltimore sponsored by Early Stage East and AstraZeneca Pharmaceuticals. Following the keynote address given by Dr. Elias Zerhouni, Director, National Institutes of Health, Lawrence Charity, ProteinOne's, Director of Marketing and Business Development presented the company's protein technology, business strategy and advancing technology role that enables scientist to bridge the divide between the Genomic and new Proteomics era.

ProteinOne will be an exhibitor at the upcoming American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, November 7-11, 2004 in Baltimore, MD and the American Society for Cell Biology (ASCB) 44th Annual Meeting, December 4-8, 2004 in Washington, DC. The AAPS meeting which takes place at the Baltimore Convention Center, provides an opportunity for pharmaceutical scientist and researchers to develop relationships with ProteinOne regarding their need to cross the divide from genomic to protein related drug developments and biomarkers. VIP Invitations are available to local scientist who are not attending the meeting, but are interested in the one day AAPS Exposition access to meet with ProteinOne and hundreds of other pharma related companies. To receive your complimentary VIP Invitation, email: info@proteinone.com.

P1 will also participate in the ASCB meeting, Dec. 4-8, 2004 at the Washington Convention Center in Washington, DC. Members of the ASCB have been research supporters of ProteinOne's product line of high quality proteins and custom protein service in understanding the dynamics of cell systems biology.

ProteinOne now offers Human Upstream Stimulatory Factor 1 (USF1), Catalog # P1062, which regulates the transcription of many genes involved in lipid and glucose homeostasis and co-localizes with familial combined hyperlipidemia (FCHL) and type 2 diabetes on chromosome 1q22-23. The USF1 protein can activate transcription through pyrimidine-rich initiator (Inr) elements and E-box motifs. It is a basic helix-loop-helix leucine zipper (b-HLH-ZIP) protein that shares a common DNA-binding specificity with the c-Myc oncoproteins.

ProteinOne now offers Simian Virus 40 Largen Antigen, Catalog# P2019, the large T antigen (TAg)of Simian virus 40 acts as an initiator of DNA replication, participates in cellular transformation, and induces cell growth. A number of functional domains have been characterized including the N-terminal J domain, nuclear localization signal (NLS), internal helicase domain, Rb and topoisomerase I interacting domain, p53 and ATP binding domain. The p53-interacting domain is also essential for binding p300/CBP. Phosphorylation of TAg by several kinases may regulate its function both positively and negatively.

ProteinOne will participate in the National Institute of Health Research Festival September 30 - October 1, 2004 on the NIH Campus in Bethesda, MD. The festival provides an opportunity for NIH investigators and researchers to dialog with ProteinOne regarding their need for custom protein expression / purifications, the upcoming release of P1's Active Protein Array - Transcription Chip and new protein products in the pipeline. NIH has had a long standing relationship with ProteinOne and is one of its largest customers.

ProteinOne, Inc. and VWR International, Inc. announced today the signing of a distribution agreement which allows VWR International the rights to market and sell Protein One's catalog products and custom services through its VWR Plus e-business purchasing solution. This agreement strengthens ProteinOne's core distribution network of its highly pure, active proteins, protein biochip platforms, purification services and adds another dimension to its promising e-business strategy. The combination of ProteinOne's technical expertise in the field of proteomics with VWR International's comprehensive e-commerce solution, vwr.com Plus, and a variety of other e-commerce tools will enhance customer service and supply chain management, and is expected to greatly facilitate customer ordering efficiency in relation to all needed lab supplies and reagents.

ProteinOne now offers a GST-tagged, Retinoic Acid Receptor. Retinoic acid receptors are important in the regulation of growth and differentiation of epithelial tissues, embryonic and central nervous system development as well as sebaceous gland activity and exhibit immunomodulatory and anti-inflammatory properties. Retinoids mediate their effect by two classes of nuclear receptor proteins, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), that each consist of three isotypes (α, β, and γ) encoded in separate genes . Current retinoid research targets the development of receptor-selective retinoids for tailoring and/or improving their therapeutic profile.

This group of closely related nuclear receptors, called peroxisome proliferator-activated receptors (PPARs), may be involved in chronic diseases such as diabetes, obesity, artherosclerosis and cancer. ProteinOne now offers the new GST tagged PPARα and the isolated GST tagged PPARα ligand binding domain as well as the three PPAR isotypes. PPARα is expressed most in brown adipose tissue and liver, then kidney, heart and skeletal muscle. PPARγ is mainly expressed in adipose tissue, and to a lesser extent in colon, the immune system and the retina. PPARβ is found in many tissues but the highest expression is in the gut, kidney and heart. PPARγ influences the storage of fatty acids in the adipose tissue.

Liver X receptors (LXRs) are nuclear receptors that regulate the metabolism of cholesterol and bile acids. ProteinOne offers the two subtypes LXRα , LXRβ , LXR isolated ligand binding domain and now the new GST-tagged, N terminal 1-182 region. LXRβ is preferentially expressed in liver, small intestine, kidney and spleen. In contrast, LXRα expression is ubiquitous. The genomic structure and the promoter regions of the two LXR genes contain specific regulatory sites, which suggest that LXRs may have physiological roles in the immune system.

OriGene Technologies and ProteinOne signed a distribution, co-marketing and technology partnership agreement, which opens the way for unprecedented advancement in functional genomics.

Researchers in Canada, China, Korea, Singapore and Israel now have convenient access to ProteinOne purified proteins, protein array platforms and custom services. Recently ProteinOne entered into distribution agreements with MJS BioLynx, Inc. of Ontario Canada, Jingmei Biotech Co. of Shenzhen, China, Benebiosis Co. of Seoul, Korea, BioFrontier Technology of Singapore and Almog Diagnostic in Shoham, Israel. These relationships contribute to the expanding international availability of ProteinOne reagents.

Cherin McKend, President of MJS BioLynx states, "With the vastly expanding biotechnology market in Canada we need to be constantly updating our knowledge and products to ensure we are bringing our customers the right tools to advance their research and to keep the Canadian growth alive. We sincerely believe that the ProteinOne products will complement our efforts."

ProteinOne is pleased to announce its call for papers. Submit your articles published in 2003 or 2004 that cite ProteinOne products and you will receive a $200 credit off your next stock protein order. This is for US customers only, one submission per article and any author on the publication may submit. Article must cite ProteinOne company and product name to qualify. Please email to lcharity@proteinone.com or Fax 301-314-6588.